Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Staphylococcal necrotizing pneumonia is a rare, bacterial, pulmonary infectious disease, caused by a Panton-Valentine leukocidin-producing Staphylococcus aureus strain, characterized by severe respiratory failure, extensive, rapidly progressing pneumonia and hemorrhagic lung necrosis. Patients typically present with influenza-like symptoms, such as fever, cough, and chest pain, as well as hemoptysis, hypotension, leukopenia, and severe respiratory symptoms that rapidly evolve to acute respiratory distress syndrome and septic shock. High mortality is associated.
Features include very common findings: Fever, Elevated white blood cell count (increased total leukocyte count), Pneumonia, and Dyspnea and others; and common findings: Low blood oxygen levels (hypoxemia), Nonproductive cough, Bacteremia, and Parenchymal consolidation and others. 38 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Lungs and breathing | 11 | Low blood oxygen levels (hypoxemia), Pneumothorax, Pulmonary infiltrates |
Biomarker and diagnostic research for staphylococcal necrotizing pneumonia has been reported in the published literature.
Phenotype severity distribution: 9 very common features, 13 common features.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for staphylococcal necrotizing pneumonia.
4 publications have been identified in PubMed for staphylococcal necrotizing pneumonia. Research spans Diagnostic / Biomarker (25%), Review / Meta-Analysis (25%), and Basic Science / Preclinical (25%).
Di Bella S (2025). [PMID: 40323347](https://pubmed.ncbi.nlm.nih.gov/40323347/). *European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology*. [Review / Meta-Analysis]
Camaione S (2025). [PMID: 40448417](https://pubmed.ncbi.nlm.nih.gov/40448417/). *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*. [Basic Science / Preclinical]
Nakaminami H (2025). [PMID: 40024689](https://pubmed.ncbi.nlm.nih.gov/40024689/). *Biological & pharmaceutical bulletin*. [Epidemiology / Natural History]
Müller E (2025). [PMID: 40137723](https://pubmed.ncbi.nlm.nih.gov/40137723/). *Pathogens (Basel, Switzerland)*. [Diagnostic / Biomarker]
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 11:11 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Blood and immune system | 4 | Low white blood cell count (decreased total leukocyte count), Immunodeficiency, Elevated white blood cell count (increased total leukocyte count) |
Lab test results | 2 | Increased circulating procalcitonin concentration, Elevated CRP (inflammation marker) (elevated circulating c-reactive protein concentration) |
Heart and blood vessels | 1 | Chest pain |
Hormones | 1 | Diabetes mellitus |
Brain and nerves | 1 | Addictive alcohol use |
Metabolism | 1 | Fever |
AI-curated news mentioning staphylococcal necrotizing pneumonia
Updated Apr 2, 2026
A retrospective analysis highlights the surgical management of necrotizing pneumonia in pediatric patients, providing insights into treatment outcomes at a third-level center. This study contributes to the understanding of surgical interventions for this severe condition.